These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21340067)

  • 1. Anticonvulsant neuropeptides as drug leads for neurological diseases.
    Robertson CR; Flynn SP; White HS; Bulaj G
    Nat Prod Rep; 2011 Apr; 28(4):741-62. PubMed ID: 21340067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities.
    Green BR; White KL; McDougle DR; Zhang L; Klein B; Scholl EA; Pruess TH; White HS; Bulaj G
    J Pept Sci; 2010 Sep; 16(9):486-95. PubMed ID: 20645434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling.
    Green BR; Klein BD; Lee HK; Smith MD; Steve White H; Bulaj G
    Bioorg Med Chem; 2013 Jan; 21(1):303-10. PubMed ID: 23176753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of monodisperse oligoethyleneglycol amino acids into anticonvulsant analogues of galanin and neuropeptide y provides peripherally acting analgesics.
    Zhang L; Klein BD; Metcalf CS; Smith MD; McDougle DR; Lee HK; White HS; Bulaj G
    Mol Pharm; 2013 Feb; 10(2):574-85. PubMed ID: 23259957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus.
    Mazarati A; Wasterlain CG
    Neurosci Lett; 2002 Oct; 331(2):123-7. PubMed ID: 12361856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities.
    Bulaj G; Green BR; Lee HK; Robertson CR; White K; Zhang L; Sochanska M; Flynn SP; Scholl EA; Pruess TH; Smith MD; White HS
    J Med Chem; 2008 Dec; 51(24):8038-47. PubMed ID: 19053761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptides in epilepsy.
    Kovac S; Walker MC
    Neuropeptides; 2013 Dec; 47(6):467-75. PubMed ID: 24210141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptides: anticonvulsant and convulsant mechanisms in epileptic model systems and in humans.
    Bajorek JG; Lee RJ; Lomax P
    Adv Neurol; 1986; 44():489-500. PubMed ID: 2871723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin: an emerging new anticonvulsant neuropeptide.
    Portelli J; Michotte Y; Smolders I
    Epilepsia; 2012 Apr; 53(4):585-95. PubMed ID: 22416903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of norepinephrine and orexigenic neuropeptides to the anticonvulsant effect of the ketogenic diet.
    Weinshenker D
    Epilepsia; 2008 Nov; 49 Suppl 8():104-7. PubMed ID: 19049603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptides as targets for the development of anticonvulsant drugs.
    Clynen E; Swijsen A; Raijmakers M; Hoogland G; Rigo JM
    Mol Neurobiol; 2014 Oct; 50(2):626-46. PubMed ID: 24705860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.
    Green BR; Smith M; White KL; White HS; Bulaj G
    ACS Chem Neurosci; 2011 Jan; 2(1):51-6. PubMed ID: 22826747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kappa opioids: therapeutic considerations in epilepsy and CNS injury.
    Tortella FC; DeCoster MA
    Clin Neuropharmacol; 1994 Oct; 17(5):403-16. PubMed ID: 9316689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.
    Hallberg M
    Med Res Rev; 2015 May; 35(3):464-519. PubMed ID: 24894913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epilepsy, CNS viral injury and dynorphin.
    Solbrig MV; Koob GF
    Trends Pharmacol Sci; 2004 Feb; 25(2):98-104. PubMed ID: 15102496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptors of peptides as therapeutic targets in epilepsy research.
    Dobolyi A; Kékesi KA; Juhász G; Székely AD; Lovas G; Kovács Z
    Curr Med Chem; 2014; 21(6):764-87. PubMed ID: 24251562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral effects of neuropeptides in rodent models of depression and anxiety.
    Rotzinger S; Lovejoy DA; Tan LA
    Peptides; 2010 Apr; 31(4):736-56. PubMed ID: 20026211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuropeptides in Alzheimer's disease].
    Jiménez-Corral C; Morán-Sánchez JC; Alonso-Navarro H
    Rev Neurol; 2006 Mar 16-31; 42(6):354-9. PubMed ID: 16575772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide therapeutics for CNS indications.
    McGonigle P
    Biochem Pharmacol; 2012 Mar; 83(5):559-66. PubMed ID: 22051078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y.
    Meurs A; Clinckers R; Ebinger G; Michotte Y; Smolders I
    Eur J Neurosci; 2007 Dec; 26(11):3079-92. PubMed ID: 18005069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.